Evaluation of the effectiveness of ivermectin in chemoprophylaxis and treatment of COVID-19 patients: A narrative review

$50.00$75.00

Authors: Alvin Chitterman, Deepak Kumar Palanichami, Anthony La, Victor Adedara, Lauren Orlando, Emmanuel O Keku, and Abidemi Fasanmi
Page Range: 57-67
Published in: International Public Health Journal, 15#1 (2023)
ISSN: 1947-4989

Table of Contents

ABSTRACT

Many drug trials have failed to produce reliable proof of efficacy in reducing the mortality and transmission of the COVID-19 virus. Apart from corticosteroids, there has been limited evidence on interventions that can prevent transmission and treat COVID-19 patients. Ivermectin has antiviral properties and is a safe, orally taken, and affordable drug. Therefore, evaluating ivermectin in chemoprophylaxis and treatment of COVID-19 patients would be necessary. This was a narrative review paper to evaluate the effectiveness of ivermectin in chemoprophylaxis and the treatment of COVID-19 patients. Using the Google Scholar database, Medline Plus, and ScienceDirect, a literature search was conducted with the keywords “COVID-19 treatment and prophylaxis” and “ivermectin treatment and prophylaxis for COVID-19 disease.” Regular ivermectin use in two randomized controlled trials (RCTs) and five observational studies has shown a statistically significantly reduced risk of COVID-19 transmission in prophylaxis trials, P < 0.05. Ten RCTs have shown a statistically significant reduction in time to patient recovery, time for viral clearance, and reduced mortality, P < 0.05. The efficacy of two RCTs showed insignificant results P > 0.05. Ivermectin is beneficial in treating and reducing COVID-19 transmissions. However, a meta-analysis is recommended to determine the pooled effect of ivermectin efficacy on COVID-19 patients.

Keywords: Coronavirus, COVID-19, SARS – CoV2, ivermectin

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!